Inflammation and cancer: advances and new agents (Q38539956)

3 September 2017

1 reference

title

Inflammation and cancer: advances and new agents (English)

1 reference

3 September 2017

2

0 references

author name string

Shanthini M Crusz

series ordinal

1

1 reference

PubMed ID

26122183

3 September 2017

language of work or name

English

0 references

publication date

30 June 2015

1 reference

Nature Reviews Clinical Oncology

3 September 2017

1 reference

3 September 2017

12

1 reference

3 September 2017

584-596

1 reference

3 September 2017

10

1 reference

Inflammation: gearing the journey to cancer

3 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Cancer-related inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Inflammation and oncogenesis: a vicious connection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Sulindac for polyposis of the colon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Estimates of benefits and harms of prophylactic use of aspirin in the general population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Contribution of platelets to tumour metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Statin use and cancer risk: a comprehensive review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

The role of cytokines in cancer cachexia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Cytokines as a key component of cancer-related inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Accessories to the crime: functions of cells recruited to the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Cancer cachexia: the molecular mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Tumour necrosis factor-alpha as a tumour promoter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

An endotoxin-induced serum factor that causes necrosis of tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Tumour necrosis factor and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Expression of tumour necrosis factor (TNFα) and its receptors in benign and malignant breast tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

TNF-alpha in promotion and progression of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Serum concentration of tumor necrosis factor in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Paraneoplastic thrombocytosis in ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Interleukin-6 as a therapeutic target in human ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Properties of the novel proinflammatory supergene "intercrine" cytokine family.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Interleukin-8 as a macrophage-derived mediator of angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Interleukin-8/CXCL8 is a growth factor for human lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Involvement of chemokine receptors in breast cancer metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

CXCR4 regulates growth of both primary and metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Inhibition of stromal CXCR4 impairs development of lung metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Stat proteins and oncogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Nuclear factor-kappaB in cancer development and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

NF-κB and the link between inflammation and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

The immune contexture in human tumours: impact on clinical outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Nivolumab plus ipilimumab in advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Macrophage activation and polarization: nomenclature and experimental guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Tumour-educated macrophages promote tumour progression and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Coordinated regulation of myeloid cells by tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Unique features of the mode of action of ET-743.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Radiation as an immune modulator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Radiation as immunomodulator: implications for dendritic cell-based immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

CpG oligodeoxynucleotide enhances tumor response to radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.105

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

31 March 2020

1 reference

12 December 2020

Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy

1 reference

12 December 2020

Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer.

1 reference

12 December 2020

Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.

1 reference

12 December 2020

Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer

1 reference

12 December 2020

Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells

1 reference

12 December 2020

Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue

1 reference

12 December 2020

Activation of human basophils through the IL-8 receptor

1 reference

12 December 2020

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists

1 reference

12 December 2020

Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype.

1 reference

12 December 2020

IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts

1 reference

12 December 2020

Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder

1 reference

12 December 2020

Interleukin-8. A corneal factor that induces neovascularization

1 reference

12 December 2020

Expression of cyclooxygenase-2 in human lung carcinoma

1 reference

12 December 2020

Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.

1 reference

12 December 2020

IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor

1 reference

12 December 2020

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors

1 reference

12 December 2020

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone

1 reference

12 December 2020

10.1038/NRCLINONC.2015.105

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

26122183